Activated protein C: cost-effective or costly?
The authors offer a commentary on the study by Dhainaut et al. on the cost-effectiveness of activated protein C in severe sepsis. Using data from "real world" conditions, the results of this economic evaluation are consistent with previous analyses, and highlight the need for "real world" investigations of new health technologies in critical care.
Brar
Savtaj Singh
SS
Manns
Braden J
BJ
D000925:Anticoagulants / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D006801:Humans; D011486:Protein C / Q000191:economics* / Q000627:therapeutic use; D018805:Sepsis / Q000188:drug therapy*
D000925:Anticoagulants; D011486:Protein C